Logo image of CRON

CRONOS GROUP INC (CRON) Stock Fundamental Analysis

NASDAQ:CRON - Nasdaq - CA22717L1013 - Common Stock - Currency: USD

2.44  -0.09 (-3.56%)

Fundamental Rating

5

CRON gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While CRON has a great health rating, there are worries on its profitability. While showing a medium growth rate, CRON is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

CRON had positive earnings in the past year.
In the past year CRON had a positive cash flow from operations.
CRON had negative earnings in 4 of the past 5 years.
In the past 5 years CRON reported 4 times negative operating cash flow.
CRON Yearly Net Income VS EBIT VS OCF VS FCFCRON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

CRON has a better Return On Assets (1.57%) than 83.94% of its industry peers.
Looking at the Return On Equity, with a value of 1.71%, CRON belongs to the top of the industry, outperforming 82.90% of the companies in the same industry.
Industry RankSector Rank
ROA 1.57%
ROE 1.71%
ROIC N/A
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
CRON Yearly ROA, ROE, ROICCRON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

1.3 Margins

CRON has a better Profit Margin (14.19%) than 89.64% of its industry peers.
In the last couple of years the Profit Margin of CRON has declined.
Looking at the Gross Margin, with a value of 32.74%, CRON is in line with its industry, outperforming 56.99% of the companies in the same industry.
Industry RankSector Rank
OM N/A
PM (TTM) 14.19%
GM 32.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
CRON Yearly Profit, Operating, Gross MarginsCRON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

8

2. Health

2.1 Basic Checks

CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRON has been increased compared to 1 year ago.
The number of shares outstanding for CRON has been increased compared to 5 years ago.
There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRON Yearly Shares OutstandingCRON Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
CRON Yearly Total Debt VS Total AssetsCRON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 7.67 indicates that CRON is not in any danger for bankruptcy at the moment.
CRON's Altman-Z score of 7.67 is amongst the best of the industry. CRON outperforms 85.49% of its industry peers.
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.67
ROIC/WACCN/A
WACC9.25%
CRON Yearly LT Debt VS Equity VS FCFCRON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

CRON has a Current Ratio of 24.65. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
CRON's Current ratio of 24.65 is amongst the best of the industry. CRON outperforms 96.37% of its industry peers.
A Quick Ratio of 23.53 indicates that CRON has no problem at all paying its short term obligations.
CRON's Quick ratio of 23.53 is amongst the best of the industry. CRON outperforms 94.82% of its industry peers.
Industry RankSector Rank
Current Ratio 24.65
Quick Ratio 23.53
CRON Yearly Current Assets VS Current LiabilitesCRON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 162.50% over the past year.
CRON shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -50.78% yearly.
Looking at the last year, CRON shows a very strong growth in Revenue. The Revenue has grown by 28.01%.
CRON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.71% yearly.
EPS 1Y (TTM)162.5%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%-400%
Revenue 1Y (TTM)28.01%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%20.51%

3.2 Future

CRON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.14% yearly.
CRON is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.39% yearly.
EPS Next Y-144.2%
EPS Next 2Y-9.67%
EPS Next 3Y-39.52%
EPS Next 5Y-21.14%
Revenue Next Year20.49%
Revenue Next 2Y12.81%
Revenue Next 3Y7.09%
Revenue Next 5Y7.39%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CRON Yearly Revenue VS EstimatesCRON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CRON Yearly EPS VS EstimatesCRON Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

1

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 48.80, CRON can be considered very expensive at the moment.
Based on the Price/Earnings ratio, CRON is valued a bit cheaper than 78.76% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.82. CRON is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 29.90 indicates a quite expensive valuation of CRON.
CRON's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CRON is cheaper than 69.43% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of CRON to the average of the S&P500 Index (35.24), we can say CRON is valued inline with the index average.
Industry RankSector Rank
PE 48.8
Fwd PE 29.9
CRON Price Earnings VS Forward Price EarningsCRON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRON Per share dataCRON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

CRON's earnings are expected to decrease with -39.52% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.67%
EPS Next 3Y-39.52%

0

5. Dividend

5.1 Amount

CRON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CRONOS GROUP INC

NASDAQ:CRON (8/19/2025, 10:56:58 AM)

2.44

-0.09 (-3.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners13.12%
Inst Owner Change7.72%
Ins Owners6.2%
Ins Owner Change12.24%
Market Cap934.62M
Analysts80
Price Target1.77 (-27.46%)
Short Float %1.29%
Short Ratio1.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-0.31%
Max Revenue beat(2)-0.21%
Revenue beat(4)1
Avg Revenue beat(4)-1.44%
Min Revenue beat(4)-14.99%
Max Revenue beat(4)9.73%
Revenue beat(8)4
Avg Revenue beat(8)1.96%
Revenue beat(12)4
Avg Revenue beat(12)-3.07%
Revenue beat(16)7
Avg Revenue beat(16)-2.54%
PT rev (1m)0%
PT rev (3m)-33.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.23%
Revenue NY rev (1m)1.73%
Revenue NY rev (3m)1.73%
Valuation
Industry RankSector Rank
PE 48.8
Fwd PE 29.9
P/S 7.17
P/FCF N/A
P/OCF 46.67
P/B 0.86
P/tB 0.93
EV/EBITDA N/A
EPS(TTM)0.05
EY2.05%
EPS(NY)0.08
Fwd EY3.34%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.05
OCFY2.14%
SpS0.34
BVpS2.83
TBVpS2.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.57%
ROE 1.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 14.19%
GM 32.74%
FCFM N/A
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 224.14%
Cap/Sales 22.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.65
Quick Ratio 23.53
Altman-Z 7.67
F-Score7
WACC9.25%
ROIC/WACCN/A
Cap/Depr(3y)70.04%
Cap/Depr(5y)158.35%
Cap/Sales(3y)6.62%
Cap/Sales(5y)22.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.5%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%-400%
EPS Next Y-144.2%
EPS Next 2Y-9.67%
EPS Next 3Y-39.52%
EPS Next 5Y-21.14%
Revenue 1Y (TTM)28.01%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%20.51%
Revenue Next Year20.49%
Revenue Next 2Y12.81%
Revenue Next 3Y7.09%
Revenue Next 5Y7.39%
EBIT growth 1Y42.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.02%
EBIT Next 3Y27.54%
EBIT Next 5Y9.95%
FCF growth 1Y90.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y120.6%
OCF growth 3YN/A
OCF growth 5YN/A